2 weeks Ago By Defense World Staff
Second Line Capital LLC lifted its holdings in Merck & Co., Inc. ( NYSE:MRK – Free Report ) by 20.
0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,634 shares of the company’s stock after acquiring an additional 772 shares during the period. Second Line Capital LLC’s holdings in Merck & Co.
, Inc. were worth $577,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK.
Industrial Alliance Investment Management Inc. boosted its holdings in Merck & Co., Inc.
by 2.6% in the 1st quarter. Industrial Alliance Investment Management Inc.
now owns 3,193 shares of the company’s stock worth $421,000 after buying an additional 80 shares during the last quarter. IRON Financial LLC lifted its position in shares of Merck & Co., Inc.
by 4.6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock valued at $224,000 after acquiring an additional 80 shares in the last quarter.
Argent Capital Management LLC boosted its stake in shares of Merck & Co., Inc. by 0.
8% in the second quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock worth $1,302,000 after acquiring an additional 81 shares during the last quarter. Forza Wealth Management LLC increased its position in shares of Merck & Co.
, Inc. by 0.8% during the second quarter.
Forza Wealth Management LLC now owns 10,480 shares of the company’s stock worth $1,297,000 after purchasing an additional 82 shares in the last quarter. Finally, Vista Investment Partners LLC raised its stake in Merck & Co., Inc.
by 2.0% in the 2nd quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock valued at $516,000 after purchasing an additional 82 shares during the last quarter.
Hedge funds and other institutional investors own 76.07% of the company’s stock. Merck & Co.
, Inc. Stock Up 0.5 % Shares of MRK opened at $113.
69 on Monday. The company’s 50-day moving average price is $116.70 and its 200 day moving average price is $124.
02. Merck & Co., Inc.
has a 12-month low of $99.14 and a 12-month high of $134.63.
The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.
80. The firm has a market cap of $287.95 billion, a P/E ratio of 126.
32, a price-to-earnings-growth ratio of 1.60 and a beta of 0.39.
Merck & Co., Inc. Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Monday, October 7th.
Stockholders of record on Monday, September 16th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Monday, September 16th.
This represents a $3.08 annualized dividend and a dividend yield of 2.71%.
Merck & Co., Inc.’s dividend payout ratio is currently 342.
22%. Wall Street Analyst Weigh In MRK has been the subject of a number of research reports. UBS Group dropped their target price on shares of Merck & Co.
, Inc. from $148.00 to $142.
00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Morgan Stanley increased their price objective on shares of Merck & Co., Inc.
from $132.00 to $134.00 and gave the company an “equal weight” rating in a report on Thursday, July 11th.
Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th.
Barclays cut their price target on Merck & Co., Inc. from $145.
00 to $142.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $155.
00 price objective on shares of Merck & Co., Inc. in a research note on Monday, September 16th.
One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc.
currently has a consensus rating of “Buy” and an average price target of $134.58. Read Our Latest Report on Merck & Co.
, Inc. About Merck & Co., Inc.
( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Further Reading Five stocks we like better than Merck & Co., Inc. What are earnings reports? Simon Property REIT: A Safe Bet for Growth and Steady Dividends EV Stocks and How to Profit from Them CarMax’s Impressive Rally: What Investors Should Watch Next Top Stocks Investing in 5G Technology MarketBeat Week in Review – 9/23 – 9/27 Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Merck & Co., Inc. ( NYSE:MRK – Free Report ).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co.
Inc. and related companies with MarketBeat.com's FREE daily email newsletter .
.
